SCHEMBL6034650

SCHEMBL6034650

CCOc1nn(-c2ccc(C(F)(F)F)cn2)cc1CCCOc1ccc(CCC(=O)O)cc1O

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 5/20 0.43
FFAR1 O14842 4/20 0.40
FFAR2 O15552 1/20 0.40
PPARA Q07869 5/20 0.38
PPARD Q03181 4/20 0.38
PPARG P37231 1/20 0.37
NR1H2 P55055 1/20 0.37
NR1H3 Q13133 1/20 0.37
S1PR1 P21453 1/20 0.36
S1PR3 Q99500 1/20 0.36
S1PR5 Q9H228 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
KDM4E B2RXH2 2/20 0.36
GCGR P47871 1/20 0.36
HPGD P15428 1/20 0.35
LMNA P02545 1/20 0.35
ROCK2 O75116 1/20 0.35
LTB4R Q15722 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6035613 0.93 TP53 (0.41) FFAR4FFAR1FFAR2PPARAPPARD
SCHEMBL6035720 0.92 SMN1; SMN2 (0.38) FFAR4FFAR1FFAR2SMN1; SMN2KDM4E
SCHEMBL6035391 0.91 FFAR4 (0.39) FFAR4FFAR1FFAR2PPARAPPARD
SCHEMBL6035545 0.91 FFAR4 (0.39) FFAR4FFAR1FFAR2PPARAPPARD
SCHEMBL6035403 0.91 FFAR4 (0.45) FFAR4FFAR1FFAR2PPARAPPARD
SCHEMBL6036172 0.89 FFAR4 (0.38) FFAR4FFAR1FFAR2PPARAPPARD
SCHEMBL6035174 0.89 FFAR4 (0.44) FFAR4FFAR1FFAR2PPARGS1PR1
SCHEMBL6337740 0.88 PPARA (0.48) PPARAPPARDPPARG
SCHEMBL6035948 0.86 PPARG (0.42) PPARAPPARDPPARGNR1H2NR1H3
SCHEMBL6034677 0.86 LTB4R (0.40) FFAR4FFAR1PPARAPPARDPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity GPR119, SLC5A1, CYP4B1 FFAR4 195/4885FFAR1 376/4885FFAR2 745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.